| Patient | Barbara Jordan |
|---|---|
| Date of birth | 1982-02-21 |
| Identifiers | MRN HR-ML030-SYN; SSN (made up) 000-30-6852 |
| Document date | 2026-03-16 |
| Author | Evangeline Moss, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review with MRI of the brain and spine, seen the same day by multiple sclerosis neurology. [S]
Ms. Jordan returns two weeks after her first visit, after MRI of the brain and spine this morning, and is seen by Dr. Watanabe of multiple sclerosis neurology on the same day. Her walking is unchanged: she uses her cane on campus and rests after about 100 meters. She has had no new symptoms and no symptom that came on over days. Her legs are stiff in the mornings. She still gets up twice a night to pass urine and sometimes has to hurry. She has started vitamin D3. The records of her original evaluation have not arrived. She asked about treatments that might slow the disease and how often she would need to be away from work for them. [S]
| Element | Detail |
|---|---|
| Walking | Cane on campus; rests after about 100 meters; unchanged |
| New symptoms | None |
| Bladder | Urgency; up twice a night |
| Imaging | MRI of the brain and cervical and thoracic spine with gadolinium this morning |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by mid-afternoon; no fever |
| Eyes | Negative | No blurred or double vision |
| Genitourinary | Positive | Urgency and nocturia twice; no burning |
| Musculoskeletal | Positive | Leg stiffness in the mornings |
| Neurological | Positive | Slowly worsening walking; no new numbness or weakness |
| Psychiatric | Negative | Mood steady |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily | One capsule daily | Oral route | 2026-03-02 | active | S |
| Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated | One tablet three times a day | Oral route | 2026-03-16 to 2026-04-20 | completed | S |
| Mirabegron 25 mg extended-release oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-16 | Body height | 173 | cm | S |
| 2026-03-16 | Body weight | 84.2 | kg | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 28.1 | kg/m2 | S |
| 2026-03-16 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-03-16 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-16 | Heart rate | 74 | /min | S |
| 2026-03-16 | Respiratory rate | 16 | /min | S |
| 2026-03-16 | Body temperature | 36.6 | Cel | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Vital signs recorded on 2026-03-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 122/76, pulse 74 |
| Neurological | Spastic paraparetic gait with a cane in the right hand; hip flexor strength 4 out of 5 on both sides; modified Ashworth 2 in both legs; brisk leg reflexes with extensor plantar responses; reduced vibration sense at the toes; EDSS 6.0; timed 25-foot walk 11.0 seconds |
| Eyes | Visual acuity 20/20 in each eye; no relative afferent pupillary defect |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine | resolved | confirmed | G35.D | S — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts. |
| Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 2017 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosis | active | confirmed | G35.B1 | S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts. |
| Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls | active | confirmed | R26.89 | S — Synthetic modern coding anchored to her documented cane. |
| Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual | active | confirmed | N31.9 | S — Synthetic; common in multiple sclerosis. No public source describes her bladder. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic laboratory finding at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | New or worsening symptoms (relapse, pseudo-relapse with heat or infection) | Every visit | Completed today | No new symptoms; relapse and pseudo-relapse plan explained with a written card |
| Examination | Disability: EDSS and timed 25-foot walk | Every visit, and at least every 6 months | Completed today | EDSS 6.0; timed 25-foot walk 11.0 seconds |
| Imaging | Brain MRI | At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium | Completed today | Diagnostic MRI with gadolinium: fourteen T2 lesions in characteristic regions; one enhancing lesion |
| Imaging | Spinal cord MRI | At diagnosis; later only for new spinal symptoms or diagnostic doubt | Completed today | Three cord lesions; no compression |
| Laboratory | Hepatitis B surface antigen, core antibody and surface antibody | Before the first dose | Up to date | All negative at intake: not infected, not immune; vaccination started today |
| Laboratory | Quantitative immunoglobulins | Before the first dose, then before each dose | Up to date | IgG 1080, IgM 110, IgA 210 mg/dL at intake |
| Laboratory | Blood count with absolute lymphocytes | Before the first dose, then before each dose | Up to date | White cells 6.4, lymphocytes 1.9 at intake |
| Laboratory | Liver tests | Before the first dose, then with symptoms and before each dose | Up to date | Normal at intake |
| Laboratory | Varicella and measles immunity, tuberculosis blood test, HIV, hepatitis C, JC virus antibody | Before the first dose | Up to date | Varicella and measles immune; tuberculosis blood test, HIV and hepatitis C negative; JC virus antibody index 0.14 |
| Medication safety | Vaccines before therapy (PCV20, recombinant zoster x2, Tdap, hepatitis B x2) | Inactivated at least 2 weeks and live at least 4 weeks before the first dose | Completed today | PCV20, zoster dose 1, Tdap and hepatitis B dose 1 today; no live vaccine needed |
| Examination | Spasticity (modified Ashworth) and baclofen tolerance | Every visit | Completed today | Modified Ashworth 2 in both legs; baclofen started |
| Examination | Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron | Every visit | Completed today | Urgency and nocturia twice; post-void residual 40 mL at intake; mirabegron started; blood pressure 122/76 |
| Referral | Falls, walking aids and physical therapy | Every visit | Ordered | No falls; physical therapy evaluation requested at intake, first appointment awaited |
| Self-management | Fatigue and heat sensitivity | Every visit | Completed today | Tires by mid-afternoon; pacing and cooling advice given |
| Laboratory | 25-hydroxyvitamin D | At baseline, 8 to 12 weeks after repletion, then yearly | Up to date | 17 ng/mL at intake; vitamin D3 started at intake |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 months and with any change | Up to date | PHQ-9 6 at intake, mostly fatigue and sleep items |
| Self-management | Workplace accommodation | At intake and with any change | Completed today | Letter describing her functional needs, without the diagnosis, given to her to send as she chooses |
| Referral | Multiple sclerosis neurology review | At diagnosis, then every 6 months on therapy | Completed today | Seen by Dr. Watanabe today |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap); Hepatitis B vaccine (HepB-CpG), dose 1 of 2 [S]
Guideline basis: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022); Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Review in five weeks for the second vaccine doses and baclofen titration; first ocrelizumab infusion to be booked at least two weeks after that visit. Same-day call for new or worsening symptoms lasting more than 24 hours. Next scheduled visit 2026-04-20: five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusion. [S]